Royalty Pharma
RPRX
643 hedge funds and large institutions have $20.5B invested in Royalty Pharma in 2026 Q2 according to their latest regulatory filings, with 106 funds opening new positions, 291 increasing their positions, 177 reducing their positions, and 43 closing their positions.
343% more call options, than puts
Call options by funds: $42.7M | Put options by funds: $9.65M
147% more first-time investments, than exits
New positions opened: 106 | Existing positions closed: 43
64% more repeat investments, than reductions
Existing positions increased: 291 | Existing positions reduced: 177
21% more capital invested
Capital invested by funds: $17B → $20.5B (+$3.55B)
9% more funds holding
Funds holding: 591 → 643 (+52)
0% more funds holding in top 10
Funds holding in top 10: 14 → 14 (0)
0.12% less ownership
Funds ownership: 82.8% → 82.69% (-0.12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$482M |
| 2 |
BlackRock
New York
|
+$100M |
| 3 |
Nordea Investment Management
Stockholm,
Sweden
|
+$93.1M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$77.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$70.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$320M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$259M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$161M |
| 4 |
Jane Street
New York
|
-$122M |
| 5 |
CIA
Caledonia Investments (Australia)
Sydney NSW,
Australia
|
-$72.5M |
RPRX Hedge Fund Activity: Q2 2026 in Review
643 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2026, worth a combined $20.5B — up 21% from $17B a quarter earlier.
Buyers outnumbered sellers: 106 funds opened new RPRX positions and 43 closed out — a net gain of 63 holders — while 291 added to existing stakes and 177 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $482M. The largest seller was Baillie Gifford & Co, cutting an estimated $320M.
- 643 institutional investors held Royalty Pharma (RPRX) as of Q2 2026, up from 591 in Q1 2026.
- Funds reported $20.5B of Royalty Pharma stock for Q2 2026, up 21% quarter-over-quarter.
- 106 funds opened new Royalty Pharma positions in Q2 2026 and 43 closed out, a net change of +63 holders.
- The largest Royalty Pharma buyer in Q2 2026 was T. Rowe Price Associates, an estimated $482M added.
- The largest Royalty Pharma seller in Q2 2026 was Baillie Gifford & Co, an estimated $320M sold.
Based on aggregated 13F filings for Q2 2026.